


# Towards a Greater Understanding of Platelet Metabolism

Rachel LeCover

ChemE 7700 Final Report

May 17, 2017



Cornell University

*School of Chemical and Biomolecular Engineering  
Cornell University, Ithaca, NY*

## Background

Platelets, small anucleate cell fragments produced by megakaryocytes, play a key role in thrombosis, the process of clot formation [1]. When the endothelium is damaged and tissue factor (TF) is exposed, the coagulation cascade commences, producing thrombin. Thrombin generation is a positive feed back loop, as thrombin can self activate from its inactive form, prothrombin. Thrombin can bind to the PAR1 receptors, present on the platelet membrane, setting off a signaling cascade inside the platelet that results in the activation of PLC $\beta$  (phospholipase C $\beta$ ), which catalyzes the conversion of PIP<sub>2</sub> (phosphatidylinositol 4,5-bisphosphate) to IP<sub>3</sub> (inositol 1,4,5 trisphosphate) and DAG [2]. The increased IP<sub>3</sub> leads to a release of calcium from the platelet's dense tubular system, which leads to an influx of calcium into the platelet from the surrounding fluid. The spike in intracellular calcium increases the activity of PLA2 (phospholipase A2), which catalyzes the production of TXA<sub>2</sub> (thromboxane A2). Activated platelets then dump the contents of their dense granules (vesicles containing ADP) into the surroundings. This ADP then interacts with the P2Y1 receptor, resulting in the inhibition of adenylate cyclase, and a decrease in cAMP concentration, allowing for a change in platelet shape [1]. Additionally, the presence of this additional calcium results in the movement of phosphatidylserine (PS) to the outer layer of platelet membranes [3].

The prothrombinase complex, consisting of active factors X and V, forms on the surfaces of platelets during coagulation<sup>1</sup>. This complex is very efficient at activating thrombin—the complete complex (with phospholipids, FXa, FVa, and calcium)<sup>2</sup> has a  $V_{max}$  of 1919 mol/min per mol FXa, compared to a  $V_{max}$  of .61 mol/min per mol FXa in the presence of only FXa [4]. Phosphatidylserine is key to the formation of the prothrombinase complex and to the normal function of the coagulation cascade, and if the scramblase that moves phosphatidylserine to the outer leaflet of the membrane does not function properly, the patient will suffer from a bleeding disorder, known as Scott syndrome [5].

**Previous Work** Since platelets play a key role in homeostasis, we may wish to understand platelet metabolism and activation. A fairly comprehensive kinetic model of platelet signaling exists, containing 77 reactions and 70 species [6], however, this model does not include the activation of platelets by thrombin. In 2014, Thomas et al published a model of platelet metabolism based on evidence from 33 human platelet proteomic studies [7]. This model contains 1008 reactions (mapped to 636 genes) and 739 compartment specific metabolites, but lacks any sort of a control system or signal transduction mechanism.

## Extension of Literature

I extended the platelet metabolic model developed by Thomas et al by adding logical rules to simulate platelet activation and by transforming it into a dynamic model as opposed to a static one. To mimic signaling, I changed the bounds of the model in response to the external concentrations of activating molecules (calcium, TXA<sub>2</sub>, and ADP). By extending this model, I hoped to understand how platelet metabolism changes during activation, and if a model that had been built to describe metabolism at steady state would change when a perturbation was applied.

---

<sup>1</sup>If you are unfamiliar with the coagulation cascade, TF activates FVII, and forms the TF-FVIIa complex, which activates FIX and FX. FX can catalyze the production of thrombin from prothrombin, but not very quickly. However, once a small amount of thrombin is generated, this thrombin can activate FV, FVIII, and FXI. The [FV-FX]<sub>a</sub> complex is very good at activating thrombin, and the [FIX-FVIII]<sub>a</sub> complex activates additional FX, resulting in a positive feed back loop.

<sup>2</sup>The a denotes active

## Mathematical Methods

**Flux Balance Analysis (FBA)** FBA permits the solving of underdetermined systems of equations, such as those found describing the flow of metabolites through a cell. This technique was used by Thomas et al to solve their model of platelet metabolism. Instead of seeking a solution for the underdetermined system of equations (Equation 2), it recasts the problem as a maximization problem, as shown in Equation 1, which can be solved via linear programming techniques, such as the Simplex method.

$$\max_{v_1, \dots, v_R} \sum_{i=1}^R c_i v_i \quad (1)$$

Subject to:

$$Sv = b \quad (2)$$

$$L_i \leq \sum_{i=1}^R \sigma_{ij} v_j \leq U_i \quad (3)$$

$$\alpha_j \leq v_j \leq \beta_j \quad (4)$$

In the above equations,  $v_i$  represents a flux through the system,  $c_i$  is the weight applied to the flux in the objective,  $S$  is the stoichiometric matrix (with elements  $\sigma_{ij}$ ),  $b$  is the residual (usually set to zero),  $L_i$  is the lower species bound for species  $i$ ,  $U_i$  is the upper,  $\alpha_j$  is the lower bound for flux  $j$ ,  $\beta_j$  is the upper bound on it.

**Dynamic Flux Balance Analysis (dFBA)** Dynamic flux balance analysis extends flux balance analysis to examine changes in flux as external conditions change, as reflected in changes in the bounds applied to the system, as shown in Equations 7 and 8.

$$\max_{v_1, \dots, v_R} \sum_{i=1}^R c_i v_i \quad (5)$$

Subject to:

$$Sv = \frac{dy}{dt} \quad (6)$$


$$L_i(t) \leq \sum_{i=1}^R \sigma_{ij} v_j(t) \leq U_i(t) \quad (7)$$

$$\alpha_j(t) \leq v_j(t) \leq \beta_j(t) \quad (8)$$

The main change is that the product of the stoichiometric matrix and the flux vector is no longer a constant, rather, it represents the changes in the concentrations of the species in the system  $\frac{dy}{dt}$ . This differential equation is solved by first solving the linear programming problem for  $v$ , and then integrating the results at discrete time points through Euler's method. I used dFBA to make the platelet model respond to changes in the external environment. Normally, for FBA or dFBA problems, an objective is chosen that maximizes cell growth or the production of a protein of interest. Since my platelets were not growing nor producing any proteins, I instead maximized the production of energetic species-ADP, NADH, and NADPH, as previously done in a model of a red blood cell [8].


## Results

**Inducing activation with ADP** By changing the bounds with respect to external ADP and calcium concentrations, I was able to mimic the deterministic simulation in [6], as shown in Figure 1.



**Fig. 1:** Red X are data from [6], black line is the dFBA simulation. This figure was generated by increasing the external ADP concentration to 20  $\mu$ M at 60 seconds.

Although far from a perfect fit, by changing the bounds I was able to capture the increase in internal calcium concentration up to about 200  $\mu$ M and its subsequent decline. In order to capture this behavior, I allowed calcium to accumulate in the model's cytoplasmic compartment, which is generally not permitted in FBA. If we compare the the flux distributions between steady state and activation, we can see that there are significant changes in platelet metabolism, especially in glycolysis, as shown in Figure 2, and in exchange reactions, shown in the supplemental material (Figure S2). Some fluxes remain the same in both cases, such as the flux through aldehyde dehydrogenase (ADD2Y) and glyceraldehyde-3-phosphate dehydrogenase (GAPD), but others are quite different. PGMT (phosphoglucomutase, the conversion of g1p(glucose 1 phosphate) to g6p (glucose 6 phosphate)) turns on, as does the flux through triose-phosphate isomerase, which produces glucose 6 phosphate from dihydroxyacetone phosphate. The flux through ENO also increases, resulting in increased production of phosphoenolpyruvate from glycerate 2-phosphate when the platelet is activated. The change in the fluxes through glycolysis leads to changes in the fluxes in pyruvate metabolism, shown in S1, since less carbon is flowing into pyruvate metabolism (a decrease in MGSA). Although the model predicts changes in the fluxes through glycolysis, experiments with radioactively labeled carbon would need to be carried out to validate these predictions.



**Fig. 3:** Differences between the norms of the fluxes between wild type and platelet with flux through reactions dependent on PTGS-1 forcibly reduced.

PGMT (phosphoglucomutase, the conversion of g1p(glucose 1 phosphate) to g6p (glucose 6 phosphate)) turns on, as does the flux through triose-phosphate isomerase, which produces glucose 6 phosphate from dihydroxyacetone phosphate. The flux through ENO also increases, resulting in increased production of phosphoenolpyruvate from glycerate 2-phosphate when the platelet is activated. The change in the fluxes through glycolysis leads to changes in the fluxes in pyruvate metabolism, shown in S1, since less carbon is flowing into pyruvate metabolism (a decrease in MGSA). Although the model predicts changes in the fluxes through glycolysis, experiments with radioactively labeled carbon would need to be carried out to validate these predictions.

**Gene Knock Outs** As previously described, the model of platelet metabolism which I extended links many of its fluxes to genes, including PTGS-1, prostaglandin-endoperoxide synthase 1 (also known as cyclooxygenase-1 (COX-1)). PTGS-1 codes for the enzyme that converts arachidonic acid to prostaglandin, which is later converted into TXA<sub>2</sub>, a key molecule in platelet signaling and activation [9]. I wished to examine how platelet metabolism would alter if the flux through these reactions was significantly decreased, simulating a mutation that negatively effected the efficiency of COX-






## References


1. R. Hoffman. *Hematology: Basic Principles and Practice*. Number v. 1 in Hematology: Basic Principles and Practice. Churchill Livingstone, 2005.
2. Lawrence F Brass. Thrombin and platelet activation. *CHEST Journal*, 124(3\_suppl):18S–25S, 2003.
3. T Lhermusier, H Chap, and B Payrastre. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in scott syndrome. *Journal of Thrombosis and Haemostasis*, 9(10):1883–1891, 2011.
4. Jan Rosing, Guido Tans, JW Govers-Riemslog, RF Zwaal, and H Coenraad Hemker. The role of phospholipids and factor va in the prothrombinase complex. *Journal of Biological Chemistry*, 255(1):274–283, 1980.
5. Maxime Halliez, Marc Fouassier, Nelly Robillard, Catherine Ternisien, Marianne Sigaud, Marc Trossaert, and Marie-Christine Bene. Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood: a simpler test for the diagnosis of scott syndrome. *British journal of haematology*, 171(2):290–292, 2015.
6. Jeremy E Purvis, Manash S Chatterjee, Lawrence F Brass, and Scott L Diamond. A molecular signaling model of platelet phosphoinositide and calcium regulation during homeostasis and p2y1 activation. *Blood*, 112(10):4069–4079, 2008.
7. Alex Thomas, Sorena Rahmanian, Aarash Bordbar, Bernhard Ø Palsson, and Neema Jamshidi. Network reconstruction of platelet metabolism identifies metabolic signature for aspirin resistance. *Scientific reports*, 4, 2014.
8. Saliha Durmuş Tekir, Tunahan Çakır, and Kutlu Ö Ülgen. Analysis of enzymopathies in the human red blood cells by constraint-based stoichiometric modeling approaches. *Computational biology and chemistry*, 30(5):327–338, 2006.
9. Thomas J Kunicki and Diane J Nugent. The genetics of normal platelet reactivity. *Blood*, 116(15):2627–2634, 2010.
10. SO Sage, TJ Rink, and MP Mahaut-Smith. Resting and adp-evoked changes in cytosolic free sodium concentration in human platelets loaded with the indicator sbfi. *The Journal of physiology*, 441:559, 1991.
11. Harvey J Motulsky and PA Insel. Influence of sodium on the alpha 2-adrenergic receptor system of human platelets. role for intraplatelet sodium in receptor binding. *Journal of Biological Chemistry*, 258(6):3913–3919, 1983.
12. Aaron Spalding, Henrikas Vaitkevicius, Scott Dill, Steven MacKenzie, Alvin Schmaier, and Warren Lockette. Mechanism of epinephrine-induced platelet aggregation. *Hypertension*, 31(2):603–607, 1998.
13. Minoru Kanehisa, Miho Furumichi, Mao Tanabe, Yoko Sato, and Kanae Morishima. Kegg: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Research*, 45(D1):D353–D361, 2017.

## Supplemental Material




**S 1:** Comparison of fluxes in pyruvate metabolism at steady state (black) and during the platelet activation process (gray). Fluxes are scaled by dividing by the upper limit on fluxes.





**S 2:** Comparison of exchange fluxes at steady state (black) and during the platelet activation process (gray). Fluxes are scaled by dividing by the upper limit on fluxes.



**S3:** Comparison of exchange fluxes at steady state for wild type (black) and knockout platelet (gray). Fluxes are scaled by dividing by the upper limit on fluxes.